Interaction between lopinavir/ritonavir and warfarin

CMAJ. Canadian Medical Association Journal

Volumn 177, Issue 4, 2007, Pages 357-359

  Hughes, Christine A ^a,c   Freitas, Andrea ^a   Miedzinski, Lilly J ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c Capital Health Edmonton   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; CLONAZEPAM; COTRIMOXAZOLE; FLUCONAZOLE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; PANTOPRAZOLE; PROTEINASE INHIBITOR; STEROID; WARFARIN; ZIDOVUDINE; ZOPICLONE;

ADULT; ANAMNESIS; ARTICLE; CANDIDIASIS; CASE REPORT; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; DEPRESSION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG WITHDRAWAL; GLUCURONIDATION; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERNATIONAL NORMALIZED RATIO; MALE; PATHOGENESIS; PNEUMONIA; SEROLOGY;

EID: 34548355091     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.061284     Document Type: Article

References (13)

1. Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Bethesda (MD): National Institutes of Health; 2006. Available: http://aidsinfo.nih.gov/ contentfiles/AdultandAdolescentGL.pdf (accessed 2007 Apr 17).
2. Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 2003;63:769-802.
3. Kaletra drug monograph. In: Repchinsky C, editor. Compendium of pharmaceuticals and specialties, online version (e-CPS). Ottawa: Canadian Pharmacists Association; 2006 (accessed 2006 July 11).
4. Niopas I, Toon S, Aarons, Rowland M. The effect of cimetidine on the steady-state pharmacokinetics and pharmacodynamics of warfarin in humans. Eur J Clin Pharmacol 1999;55:399-404.
5. Warfarin drug monograph. In: Repchinsky C, editor. Compendium of pharmaceuticals and specialties, online version (e-CPS). Ottawa: Canadian Pharmacists Association; 2006 (accessed 2006 July 11).
6. Ufer M. Comparative pharmacokinetics of vitamin K antagonists. Clin Pharmacokinet 2005;44:1227-46.
7. Knoell KR, Young TM, Cousins ES. Potential interaction involving warfarin and ritonavir. Ann Pharmacother 1998;32:1299-302.
8. Gatti G, Alessandrini A, Cemera M, et al. Influence of indinavir and ritonavir on warfarin anticoagulant activity. AIDS 1998;12:825-6.
9. Newshan G, Tsang P. Ritonavir and warfarin interaction. AIDS 1999;13:1788-9.
10. Darlington MR. Hypoprothrombinemia during concomitant therapy with warfarin and saquinavir [letter]. Ann Pharmacother 1997;31:647.
11. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005;165:1095-106.
12. Yeh RF, Gaver VE, Patterson KB, et al. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr 2006;42:52-60.
13. Lim ML, Min SS, Sherene S, et al. Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. J Acquir Immune Defic Syndr 2004;36:1034-40.